TransCode Therapeutics, Inc. (RNAZ)

NASDAQ: RNAZ · IEX Real-Time Price · USD

0.296

-0.006 (-2.02%)

At close: Jul 26, 2024, 4:00 PM

0.342

+0.046 (15.70%)

After-hours: Jul 26, 2024, 7:59 PM EDT

TransCode Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018
Selling, General & Admin	6.39	7.15	8.4	3.4	0.44	0.23	Upgrade
Research & Development	11.43	12.26	10.23	2.75	0.28	0.23	Upgrade
Operating Expenses	17.82	19.42	18.63	6.15	0.73	0.46	Upgrade
Operating Income	-17.82	-19.42	-18.63	-6.15	-0.73	-0.46	Upgrade
Interest Expense	-0.05	-0.06	-0.03	-0.1	-0.39	-0.16	Upgrade
Interest & Investment Income	0	0.01	0.02	0	0	0	Upgrade
Currency Exchange Gain (Loss)	-0.06	-	-	-	-	-	Upgrade
Other Non Operating Income (Expenses)	0.87	0.92	1.08	-0.59	-1.22	0.01	Upgrade
EBT Excluding Unusual Items	-17.06	-18.55	-17.56	-6.84	-2.34	-0.61	Upgrade
Gain (Loss) on Sale of Assets	-	-	-	-0	-	-	Upgrade
Pretax Income	-17.06	-18.55	-17.56	-6.84	-2.34	-0.61	Upgrade
Net Income	-17.06	-18.55	-17.56	-6.84	-2.34	-0.61	Upgrade
Net Income to Common	-17.06	-18.55	-17.56	-6.84	-2.34	-0.61	Upgrade
Shares Outstanding (Basic)	1	0	0	0	-	-	Upgrade
Shares Outstanding (Diluted)	1	0	0	0	-	-	Upgrade
Shares Change (YoY)	8582.47%	1003.48%	54.03%	-	-	-	Upgrade
EPS (Basic)	-11.68	-103.61	-1082.79	-649.77	-	-	Upgrade
EPS (Diluted)	-11.68	-103.61	-1082.79	-649.77	-	-	Upgrade
Free Cash Flow	-17.52	-18.11	-15.86	-5.52	-0.49	-0.51	Upgrade
Free Cash Flow Per Share	-12.00	-101.17	-977.90	-524.28	-	-	Upgrade
EBITDA	-17.69	-19.3	-18.54	-6.11	-	-	Upgrade
D&A For EBITDA	0.13	0.12	0.1	0.04	-	-	Upgrade
EBIT	-17.82	-19.42	-18.63	-6.15	-0.73	-0.46	Upgrade

Source: S&P Capital IQ. Standard template.